機能性:

• IBS に関連する胃腸の不快感の軽減
• 腸内細菌叢のバランスを整える
• 非伝染性リファマイシン耐性
• 菌体外多糖（エキソポシサッカリド）の生成

学術サポート:

ヒト臨床試験

1. Amenta M. et al. Diet and chronic constipation. Benefits of oral supplementation with symbiotic zir fos (Bifidobacterium longum W11 + FOS Actilight). Acta Biomed 2006; 77(3):157-62.
2. Colecchia A. et al. Effect of a symbiotic preparation on the clinical manifestations of irritable bowel syndrome, constipation-variant. Results of an open, uncontrolled multicenter study. Minerva Gastroenterol Dietol 2006; 52(4):349-58.
3. Fanigliulo L. et al. Role of gut microflora and probiotic effects in the irritable bowel syndrome. Acta Biomed 2006; 77(2):85-9.
4. Sarnelli G. et al. Effects of oral supplementation with the symbiotic (Bifidobacterium longum W11 + FOS Actilight) on IBS with constipation: a randomized, dose finding trial, versus fibers. Digestive and Liver Disease 2008; 40(1):S141.
5. Malaguarnera M. et al. Bifidobacterium longum with fructo-oligosaccharides (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Dig Dis Sci 2007; 52:3259-3265.
6. Dughera L. et al. Effects of symbiotic preparation on constipated irritable bowel syndrome symptoms. Acta Biomed 2007; 78:111-116.
7. Del Piano M. et al. Clinical Experience With Probiotics in the Elderly on Total Enteral Nutrition. J Clin Gastroenterol 2004;38:S111-S114.

インビトロ研究

1. Graziano T. et al. The possible innovative use of Bifidobacterium longum W11 in association with rifaximin: a new horizon for combined approach? J Clin Gastroenterol. 2016 Nov/Dec;50 Suppl 2, Proceedings from the 8th Probiotics, Prebiotics & New Foods for Microbiota and Human Health meeting held in Rome, Italy on September 13-15, 2015:S153-S156.
2. Inturri R. et al. Complete Genome Sequence of Bifidobacterium longum W11 (LMG P-21586), Used as a Probiotic Strain. Genome Announc. 2017 Mar 9;5(10). pii: e01659-16. doi: 10.1128/genome A.01659-16.
3. Inturri R. et al. Chemical and biological properties of the novel exopolysaccharide produced by a probiotic strain of Bifidobacterium longum, Carbohydrate polymers / Elsevier 2017.
4. Medina et al. Differential immunomodulatory properties of Bifidobacterium longum strains: relevance to probiotic selection and clinical applications, Clinical and Experimental Immunology, 2007.
5. Izquierdo E. et al. Resistance to Simulated Gastrointestinal Conditions and Adhesion to Mucus as Probiotic Criteria for B. longum strains. Curr Microbiol 2008, 56:613-618.
6. Interri R. et al. Scanning Electro Microscopy Observation of Adhesion Properties of B. longum W11 and Chromatographic Analysis of Its Exopolysaccharide 2014, Food and Nutrition Sciences 1787-1792.
7. Interri R. et al. Immunomodulatory Effects of B. longum W11 Produced Exopolysaccharide on Cytokine Production. 2017, Current Pharmaceutical Biotechnology.
8. B. longum W11, an antibiotic resistant probiotic, Di Pierro 2018, CEC online article: http://ceceditore.com/bifidobacterium-longum-w11-anantibiotic-resistant-probiotic/?lang=en.

臨床研究における 1 日の投与量:
1,2,3,4,5,6,7) 5 billion CFU + FOS

機能性:

• 腸内細菌叢のバランスを整える

学術サポート:
インビトロ研究
Del Piano M. et al. In Vitro Sensitivity of Probiotics to Human Pancreatic Juice. J. Clin. Gastroenterol. Vol 42, Suppl. 3, Part 2, Sept. 2008. (LA02, LPC00).

機能性:

• 便秘
• 腸管煽動

学術サポート:

ヒト臨床試験
Del Piano M. et al. The use of probiotics in the treatment of constipation in the elderly (BL03, LP01, BS01, LR05, BA02 and BR03 seperately). CIBUS, 2005; 1(1):23-30.

a) Del Piano M. et al. In Vitro Sensitivity of Probiotics to Human Pancreatic Juice (LA02, LPC00, LP01, LR04, BR03, BL03 and BA02). J Clin Gastroenterol. Vol 42, Suppl. 3, Part 2, Sept. 2008.
b) Rossi M. et al. fermentation of fructooligosaccharides and inulin by Bifidobacteria: a comparative study of pure and fecal cultures (BA02). Applied and Environmental Microbiology, 2005;71(10):6150-6158.

臨床研究における 1 日の投与量:
10 billion CFU

利用可能形態: 製剤

機能性:

• 葉酸の生成
• 腸内菌叢のバランスを整える

学術サポート:

パイロットヒト臨床試験
Strozzi GP. and Mogna L. Quantification of folic acid in human faeces after administration of Bifidobacterium probiotic strains. Journal of Clinical Gastroenterology, 2008; 42:S179-S184.

Pompei A. et al. Administration of Folate-Producing Bifidobacteria Enhances Folate Status in Wistar Rats. Journal of Nutrition, 2007; 137:2742-2746.

Pompei A. et al. Folate production by Bifidobacteria as a potential probiotic property. Applied and Environmental Microbiology, 2007; 73(1):179-185

臨床研究における 1 日の投与量:
5 billion CFU

可能形態: 原料、あるいは製剤

機能性:

• 腸内菌叢のバランスを整える
• 腸管煽動
• 胃腸の不快感の軽減
• 毒素原性 O157:H7 を含む大腸菌の阻害

学術サポート:

ヒト臨床試験

1. Del Piano M. et al. Evaluation of the intestinal colonization by microencapsulated probiotic bacteria in comparison with the same uncoated strains. J Clin Gastroenterol. 2010; 44 Suppl 1:S42-6.
2. Del Piano M. et al. Is microencapsulation the future of probiotic preparations? The increased efficacy of gastro-protected probiotics. Gut microbes. 2011; 2(2):120-3

インビトロ研究

1. Nicola S. et al. Interaction between probiotics and human immune cells: the prospective anti-inflammatory activity of Bifidobacterium breve BR03. AgroFOOD, 2010; 21 (2): S44-47.
2. Mogna L. et al. Assessment of the in vitro inhibitory activity of specific probiotic bacteria against different Escherichia coli strains. J Clin Gastroenterol. 2012; 46 Suppl:S29-32

可能形態: 原料、あるいは製剤

機能性:

• 腸内菌叢のバランスを整える